Fosun Pharma adjusts 2025 equity incentive plans for 195 employees

Shanghai Fosun Pharmaceutical Group (SSE:600196) approved the initial grant for its 2025 A-share stock option and H-share restricted share unit (RSU) incentive plans on November 4, 2025. The number of eligible recipients for both plans was adjusted from 201 to 195 due to six proposed recipients no longer being employed.

Consequently, A-share options were adjusted from 4,580,900 to 4,535,100 units, with an exercise price of RMB 27.93 per share. H-share RSUs were adjusted from 10,696,400 to 10,589,500 units, with an exercise price of RMB 1.00 per unit. The estimated cost for the A-share option plan is RMB 1,236 million, to be expensed over the vesting periods.

The plans include current executive directors, employee directors, senior management, and core technical staff. The validity period for the A-share options is up to 60 months from the grant date, with vesting in three tranches: 33% after 12 months, 33% after 24 months, and 34% after 36 months.